title: Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy.
abstract: Immunotherapy with recombinant interleukin-2 (rIL-2) activated natural killer cells (ANK) may be useful in the treatment of malignancies. Difficulties in large scale cultivation of purified ANK have hampered clinical trials. In a first set of experiments designed to characterize ANK precursors in blood we demonstrated that both FACS purified CD56+/CD3- and CD56-/CD3- cultured with rIL-2 give rise to an expanded cell population bearing the CD56+(bright)/CD3- phenotype and having both NK and lymphokine-activated killer (LAK) activity. Cultivation of NK was markedly enhanced by autologous monocytes. We next demonstrated that panning of peripheral blood stem cells on CD5/CD8 coated flasks yielded a starting population enriched for monocytes and NK precursors which after cultivation resulted in production of 4 x 10(10) highly cytotoxic ANK adequate for in vivo clinical trials. Finally, we demonstrated that ANK generated in high dose IL-2 maintain NK and LAK activity for up to 6 days when cultured in as little as 1 U/ml rIL-2. This may allow infusion of ANK with a rIL-2 dose achievable in vivo that does not produce significant systemic toxicity. We plan to test the efficacy of ANK to prevent relapse in a minimal residual disease state following autologous bone marrow transplant.
authors.affiliation: Department of Medicine, University of Minnesota Medical School, Minneapolis 55455.
authors.forename: J S
authors.initials: JS
authors.lastname: Miller
authors.forename: S
authors.initials: S
authors.lastname: Klingsporn
authors.forename: J
authors.initials: J
authors.lastname: Lund
authors.forename: E H
authors.initials: EH
authors.lastname: Perry
authors.forename: C
authors.initials: C
authors.lastname: Verfaillie
authors.forename: P
authors.initials: P
authors.lastname: McGlave
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D018956:CD5 Antigens; D016827:CD8 Antigens / Q000032:analysis; D002469:Cell Separation / Q000379:methods*; D006412:Hematopoietic Stem Cells; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; D018956:CD5 Antigens; D016827:CD8 Antigens; D007376:Interleukin-2; D011994:Recombinant Proteins